Importance: the XEN-45 implant, a hydrophilic collagen implant which drains aqueous to the subconjunctival space, has not been investigated in the context of uveitic glaucoma. Background: to determine the safety and efficacy of the XEN-45 collagen implant in eyes with uveitic glaucoma. Design: exploratory prospective case series. Participants: patients with medically uncontrolled uveitic glaucoma. Methods: twenty-four consecutive patients (mean age AE standard deviation [SD] = 45.3 AE 18.1 years) were implanted with the XEN-45 implant. Main Outcome Measures: the primary outcome measure was intraocular pressure (IOP) reduction at 12 months as compared to baseline. Secondary outcome measures included ocular hypotensive medication use at 12 months, the requirement for further glaucoma surgery and failure. Intraoperative and postoperative complications were documented. Results: the baseline mean AE SD IOP was 30.5 AE 9.8 mmHg and the mean AE SD number of glaucoma medications required was 3.3 AE 0.8. In 20 eyes (83.3%) in whom conventional glaucoma surgery was originally perceived to be inevitable, further surgery was not required after XEN-45 implantation. The mean IOP was reduced by 60.2% from baseline to 12.2 AE 3.1 mmHg and mean medication usage was reduced to 0.4 AE 0.9 at 12 months (both P < 0.001). One patient had hypotony persisting beyond 2 months that required surgical revision and one patient developed blebitis. The 12-month cumulative Kaplan-Meier survival probability was 79.2%. Conclusions and Relevance: the XEN-45 implant is effective for the treatment of patients with medically uncontrolled uveitic glaucoma. Potentially sight-threatening complications, including blebrelated ocular infection and persistent hypotony, may occur.
INTRODUCTION
The XEN-45 implant (Allergan plc, Dublin, Ireland) is a hydrophilic collagen implant comprised of cross-linked porcine gelatin, which drains aqueous from the anterior chamber to the subconjunctival space. 1 It has an inner lumen of approximately 45 μm and surgical implantation of the device is minimally invasive. 2, 3 The XEN-45 implant has obtained United States Food and Drug Administration approval and the Conformité Européene Mark. The lumen size and length of the implant have been claimed to provide approximately 6-8 mmHg pressure resistance according to the Hagen-Poiseuille equation, so as to confer protection against hypotony. 1 An ab interno surgical approach was found to cause less scarring from conjunctival trauma compared to the ab externo approach, resulting in a longer duration of drainage than trabeculectomy in rabbits. 4 Glaucoma is a common and sight-threatening complication of uveitis, [5] [6] [7] and the management of uveitic glaucoma remains challenging. Glaucoma surgery is indicated when the intraocular pressure (IOP) is uncontrolled despite maximum tolerated medical therapy, or when the patient has been prescribed a significant dose of systemic carbonic anhydrase inhibitors, so that associated side effects can be avoided. 8 Conventional glaucoma procedures, such as trabeculectomy and aqueous shunt (Baerveldt, Ahmed and Molteno) implantation, are associated with an increased incidence of postoperative complications in uveitic eyes undergoing glaucoma surgery, including ocular hypotony, cystoid macular oedema and choroidal effusions. 7, [9] [10] [11] [12] [13] Hence, the high safety profile of micro-invasive glaucoma surgery (MIGS) renders it potentially advantageous in the context of uveitic glaucoma compared to conventional glaucoma surgeries. 6, 7 The aim of this pilot study was to determine the safety and efficacy of the XEN-45 implant in eyes with uveitic glaucoma and uncontrolled IOP.
METHODS
This was a single-centre exploratory prospective single-cohort study of 24 consecutive patients who underwent XEN-45 implantation for uveitic glaucoma by a variety of trained surgeons. The study was approved by the institutional review board and adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from all patients prior to XEN-45 implantation.
Study subjects
We included patients with medically uncontrolled uveitic glaucoma (medicated IOP greater than 21 mmHg) who underwent XEN-45 implantation (Allergan plc, Dublin, Ireland). The definition of glaucoma by Foster et al.
14 was used in this study and all patients had a definite visual field defect consistent with glaucoma. Prior to surgery, all patients required at least three glaucoma medications and 11 patients required oral acetazolamide (≥500 mg/day). All patient had open angles (Shaffer grade 3 or 4) as assessed by gonioscopy. Only patients with healthy, free and mobile conjunctiva in the target superior-nasal quadrant were selected for the surgery.
Exclusion criteria included conjunctival scarring or other types of conjunctival pathology (e.g. pterygium) in the target quadrant, previous incisional glaucoma surgery, angle closure or Shaffer grade 1 or 2 angles, previous ocular trauma resulting in angle recession, neovascularization of the iris or the angle, and known or suspected allergy or sensitivity to any of the device components (e.g. glutaraldehyde or porcine products).
Surgical technique
In all cases, 0.1 ml of 0.2 mg/mL mitomycin C was injected subconjunctivally in the superior-nasal quadrant of the eye 5-10 min prior to implantation of the XEN-45 implant. A 1.1-mm corneal incision was made in the inferior-temporal cornea with a 20 gauge MVR knife (Bausch & Lomb, Tampa, FL, USA), approximately 1 mm anterior to the limbus, at approximately the 4 o'clock position for the left eye and 10 o'clock position for the right eye. The anterior chamber was filled with viscoelastic (Healon GV; Abbott Medical Optics, Abbott Park, IL, USA). The preloaded inserter needle was introduced through the corneal incision and directed across the anterior chamber to the superior-nasal quadrant of the angle, inserted through the angle and the sclera, and exiting the sclera approximately 3 mm posterior to the limbus. The XEN-45 implant was injected into the subconjunctival space and the injector needle withdrawn from the eye. The viscoelastic was evacuated completely using irrigation and aspiration at the end of the surgery and the cornea incision was hydrated. A subconjunctival bleb was noted around the implant in all patients at the end of surgery. Contact with the iris, lens and the corneal endothelium was avoided during the implantation procedure. After surgery, all glaucoma medications were discontinued and all patients were prescribed topical antibiotics for 2 weeks and topical dexamethasone 0.1% for at least 3 months. The frequency of topical steroid therapy was initially 2 h and tapered according to the extent of conjunctival injection around the bleb and the activity of uveitis.
Study measures
Study subjects had a complete ophthalmic examination by a fellowship-trained glaucoma specialist preoperatively and on day 1, week 1 and months 1, 3, 6, 9 and 12 postoperatively. This includes a detailed slit lamp examination of the anterior and posterior segments, assessment of the best corrected Snellen visual acuity (BCVA) and IOP measurement with Goldmann applanation tonometry. The IOP was assessed in the morning for each study visit, and ocular hypotensive medications added if the IOP exceeded the target IOP according to the Canadian Consensus Guidelines. 15 Gonioscopy was performed with a four-mirror goniolens (Volk Optical, Inc., Mentor, OH, USA) under dark conditions using a narrow beam of light (1 × 1 mm). Preoperatively, the angle in the target quadrant (superior-nasal) was graded using the Shaffer classification. 16, 17 After XEN-45 implantation, gonioscopy was also used to verify correct implant placement if it was not visible in the anterior chamber on slit lamp examination. Preoperative automated perimetry was performed with the Humphrey Visual Field 24-2 Swedish Interactive Threshold Algorithm (SITA) standard program.
The primary outcome measure was IOP reduction at 12 months as compared to baseline. Secondary outcome measures included ocular hypotensive medication use at 12 months, the requirement for additional glaucoma surgery (trabeculectomy and aqueous shunt) and failure. Failure was defined as IOP exceeding 21 mmHg or less than 20% reduction below baseline on two consecutive follow-up visits after 3 months, IOP ≤ 5 mmHg on two consecutive follow-up visits after 3 months, reoperation for glaucoma or loss of light perception vision. 18 Postoperative complications were noted at each visit, including ocular hypotony (IOP <6 mmHg), 19 transient IOP elevation (defined as IOP ≥ 30 mmHg during a study visit but resolved with reintroduction of glaucoma medications or bleb needling), 20 hyphaema, loss of ≥2 lines of BCVA, implant exposure, suprachoroidal haemorrhage, blebitis, endophthalmitis, cystoid macular oedema or persistent corneal oedema. If ocular hypotony was noted postoperatively in association with a shallow anterior chamber, up to 0.1 ml of a viscoelastic agent (Provisc; Alcon Laboratories, Inc., Fort Worth, TX, USA) was injected into the anterior chamber. However, viscoelastic injection was not routinely performed if the anterior chamber was deep despite ocular hypotony. Bleb needling was performed if there was an absence of a subconjunctival filtering bleb and the IOP was ≥21 mmHg. Surgical revision of the bleb with Tenon's dissection was performed in the operating room if there was extensive subconjunctival scarring around the implant. The number of viscoelastic injections, needling procedures and bleb revisions were noted for each patient.
Statistical analysis
Descriptive statistics were used to describe baseline characteristics for the study patients. The frequency distribution and percentages were calculated for categorical data and the mean values and standard deviations were calculated for continuous data. All patients were included in the safety analysis based on the incidence of surgical complications. To assess the efficacy of the XEN-45 implant, postoperative IOP and hypotensive medication use at 12 months were compared to baseline using the Wilcoxon signed-rank test. We excluded eyes which were re-operated on from the efficacy analysis as additional glaucoma surgery could confound the results. Kaplan-Meier analysis was used to describe cumulative probabilities of survival in our study cohort amongst uveitis subtypes. Cox regression was used to assess possible factors associated with failure (i.e. age, pseudophakia, preoperative IOP, number of preoperative glaucoma medications, preoperative steroid use). P < 0.05 was considered statistically significant.
RESULTS
Demographic data and baseline characteristics of the study subjects are shown in Table 1 .
Preoperatively, 17 patients were phakic and seven patients were pseudophakic. One patient had a uveitis flare-up within 1 month prior to the surgery but the rest of the patients had quiescent uveitis for at least 3 months before XEN-45 implantation. Preoperatively, 14 patients required longterm maintenance topical steroids, of whom two patients were also prescribed oral prednisolone and one patient was prescribed methotrexate.
The XEN-45 implant was successfully inserted in all 24 eyes of 24 patients. Twenty-two eyes underwent XEN-45 implantation as a solo procedure, whereas two eyes underwent combined XEN-45 implantation with cataract surgery. Correct implant positioning was confirmed by slit lamp examination or by gonioscopy when the implant was not visible in the anterior chamber on slit lamp examination (Figs 1,2 ). There were no sight-threatening intraoperative complications. Intraoperative hyphaema occurred in one eye as a consequence of the implant being inserted too posteriorly. The malpositioned implant was removed and a second implant was inserted. There were no other intraoperative complications in the other 23 eyes.
The most common postoperative complication was transient postoperative IOP elevation, which occurred in 15 eyes (62.5%). In nine eyes, IOP elevation occurred within the first 3 months after XEN-45 implantation. Postoperative bleb needling at the slit lamp was required in 10 eyes (41.7%) to achieve a diffuse bleb morphology (Fig. 3 ). Bleb revision with Tenon's dissection was also performed in the operating room on five eyes with extensive subconjunctival scarring around the implant in association with raised IOP (within the first 4 months after XEN-45 implantation), of which two eyes underwent one prior bleb needling at the slit lamp. Postoperative hyphema was present in two eyes (8.3%) but resolved within the first postoperative week. Postoperative hypotony was noted in nine eyes (37.5%), which resolved within 2 weeks in eight eyes. Of these, five eyes (20.8%) had hypotony in association with a shallow anterior chamber, and required anterior chamber reformation with viscoelastic. One patient (4.2%) had persistent hypotony and a choroidal effusion 2 months after XEN-45 implantation, and required bleb revision with drainage of the choroidal effusion. This patient subsequently developed persistent corneal oedema at 1 year, which was thought to be secondary to multiple surgical procedures. Implant exposure occurred in two eyes (at postoperative month 3 and postoperative month 4, respectively) and required surgical conjunctival closure. Three eyes (12.5%) lost ≥2 lines of BCVA due to cataract progression after XEN-45 implantation, but did not undergo cataract surgery within the study period. Two eyes had preexisting cataracts and underwent cataract surgery 3 months after XEN-45 implantation. One eye developed blebitis (4.2%) 9 months after XEN-45 implantation due to an avascular bleb. There was no vitritis and conjunctival culture grew Staphylococcus aureus. The blebitis resolved after topical antibiotics were administered, with a good visual recovery to 6/9 Snellen visual acuity ( Table 2) .
Before XEN-45 implantation, it had been anticipated that conventional incisional glaucoma surgery would be indicated in all eyes. Of these, 20 eyes (83.3%) did not require further glaucoma surgery during the 12 months of follow-up, whereas four eyes (16.7%) required additional incisional glaucoma surgery due to uncontrolled IOP (mean = 30.8 AE 6.2 mmHg) despite maximum glaucoma medications (mean = 3.5 AE 1.0). Baerveldt aqueous shunt implantation was performed on three eyes and trabeculectomy with mitomycin C was performed on one eye.
At the 12-month visit, 19 eyes were available for efficacy evaluation. Four eyes were excluded because conventional incisional glaucoma surgery was performed and one eye was excluded because the patient defaulted the 12-month follow-up visit. In a paired analysis of these 19 eyes, the mean IOP was reduced by 60.4% from 30.7 AE 9.7 mmHg at baseline to 12.2 AE 3.1 mmHg at 12 months (P < 0.001). The mean number of topical ocular hypotensive medications was reduced from 3.1 AE 0.9 at baseline to 0.4 AE 0.9 at 12 months (P < 0.001), with an average reduction of 2.7 medications per subject. None of the 19 eyes required oral acetazolamide after XEN-45 stent implantation, and 15 eyes (62.5%) did not require any topical glaucoma medications 12 months after XEN-45 stent implantation. Four eyes required glaucoma medications at 12 months, of which two eyes required three medications, one eye required two medications and one eye required one medication.
The 12-month cumulative Kaplan-Meier survival probability was 79.2% (Fig. 4) . Eyes that had intermediate uveitis (n = 4) had lower survival probability at 12 months compared to other eyes in the study 
DISCUSSION
In this pilot study, ab interno insertion of the XEN-45 collagen implant was effective in avoiding conventional glaucoma filtration surgery in 83.3% of the patients with medically uncontrolled uveitic glaucoma for at least 12 months, resulting in a significant decrease in IOP and the number of glaucoma medications. Potentially, sight-threatening complications may be associated with XEN-45 implantation, including persistent hypotony and bleb-related ocular infection, although the incidence of these was low.
We present novel data on the efficacy and safety of the XEN-45 implant in eyes with uveitic glaucoma and uncontrolled IOP. To our knowledge, there are currently no published studies on the clinical efficacy of the XEN-45 implant in eyes with uveitic glaucoma. All patients included in this study required surgical intervention because of uncontrolled IOP despite being on three or more ocular hypotensive medications. XEN-45 implantation averted conventional glaucoma filtration surgeries in 83.3% of the patients in our study for at least 12 months. In these patients who did not require subsequent glaucoma surgery, there was a significant decrease in IOP by approximately 60%, and a reduction in the number of glaucoma medications by approximately 2.7 medications. The 12-month cumulative Kaplan-Meier survival probability was 79.2%. Our data suggest that intermediate uveitis was associated with a lower survival probability of 25% at 12 months, although the numbers were small (n = 4). Hence, this finding requires verification in a larger cohort. Remarkably, despite the markedly elevated preoperative IOP which could not be controlled by at least three medications, 62.5% of the patients did not require any glaucoma medications in the operated eye 12 months after XEN-45 stent implantation. In addition, if further glaucoma procedures are indicated in the future, the superior and temporal conjunctiva is preserved for trabeculectomy and tube shunt implantation.
The 12-month efficacy of the XEN-45 implant in our study is unexpectedly encouraging for a MIGS device, the efficacy of which is thought to be modest compared to conventional glaucoma filtration surgery in exchange for a more favourable safety profile.
2,3 Our preliminary results suggest that the XEN-45 implant may be more effective in lowering the IOP compared to other available MIGS devices. The XEN-45 implant, like conventional glaucoma filtration surgery, drains aqueous to the subconjunctival space. Surgical implantation of the XEN-45 gel implant requires approximately 10 min, compared to the duration of trabeculectomy or tube shunt implantation surgery which may take an hour or more. Ab interno insertion of the XEN implant does not involve conjunctival dissection; hence, occlusion of the implant lumen (which has an internal diameter of only 45 μm) with Tenon's fascia or subconjunctival fibrosis occurs frequently after the surgery, resulting in elevated IOP. To achieve a functioning bleb, postoperative bleb manipulation was required in a significant proportion of patients, with needling required in 41.7% of the eyes within the first 12 months of surgery, and bleb revision with Tenon's dissection required in five eyes (20.8%) . This is the first study investigating the use of the XEN-45 implant in the context of uveitic glaucoma. Conventional glaucoma procedures are associated with a higher rate of postoperative complications in uveitic eyes compared to eyes with primary glaucoma. 7, 8, [11] [12] [13] 21, 22 Although XEN-45 implantation averted conventional glaucoma surgery in 83.3% of the eyes in our study, it was also associated with potentially sight-threatening complications, including persistent hypotony and bleb-related ocular infection. MIGS is typically characterized by a favourable safety profile, and this is the first report of serious and potentially sight-threatening complications resulting from a MIGS device. Notably, these serious complications have not been reported after XEN-45 implantation in eyes with primary open angle glaucoma. [23] [24] [25] In comparison, ab interno trabeculectomy with the Trabectome was found to be effective for the treatment of uveitic glaucoma but was not associated with persistent hypotony or ocular infections. 26, 27 In our study, there was a high rate of transient postoperative hypotony associated with a shallow anterior chamber, with approximately 20% of patients requiring anterior chamber reformation with viscoelastic. Transient IOP elevation occurred in 62.5% of our study patients. Hence, XEN-45 implantation may be more appropriate in uveitic eyes with mild to moderate visual field loss, as such IOP spikes may result in wipe-out in eyes with advanced visual field loss. Three eyes (12.5%) lost ≥2 lines of BCVA due to cataract progression after XEN-45 stent implantation, likely secondary to the use of postoperative steroid eye drops. Despite the material of the XEN-45 implant being soft and tissue-conforming, implant exposure occurred in two eyes (8.3%) in our study and has also been reported previously. 25, 28, 29 Our study was limited by the small number of patients. There was insufficient statistical power to identify the predictors of failure. The 12-month duration of follow-up in our study did not allow us to detect late complications or evaluate for glaucoma progression. A larger study should investigate the long-term results of this device in uveitic eyes as well as eyes with primary glaucoma. Information on bleb vascularity, elevation and area was not available in our study. We aimed to position the XEN-45 implant in the subconjunctival space above Tenon's fascia, so that the implant would be easily visible if bleb needling was required. Subconjunctival placement of the XEN-45 implant would also reduce the risk of occlusion with Tenon's fascia. However, in patients with thick Tenon's fascia, it was not always possible to ensure subconjunctival implant placement as targeted, and a few implants may have been inadvertently placed in the subTenon's space.
In conclusion, this pilot study provides novel data on the clinical efficacy of the XEN-45 implant in eyes with uveitic glaucoma. Our results suggest that XEN-45 implantation is an effective treatment option for patients with medically uncontrolled uveitic glaucoma, averting conventional glaucoma surgery in 83.3% of patients and 62.5% of the eyes were medication-free for at least 12 months. However, potentially sight-threatening complications, including bleb-related ocular infection and persistent hypotony, may occur. These findings require verification in a larger study with a longer-follow-up.
